Author Archives: Gastroenterology Journal
IMPLICATIONS OF ADOLESCENT AND PARENT PERCIEVED SKILL-BUILDING ON MISCARREID HELPING AND SELF-EFFICACY FOLLOWING A TRANSITION WORKSHOP FOR ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE
The rising prevalence of Inflammatory Bowel Disease (IBD) in children and subsequent need for continued care into adulthood, begets the call for patient education on the transition to adult healthcare. To address this need, we designed a virtual, trans… Continue reading
THE ROLE OF GROUP 3 INNATE LYMPHOID CELLS (ILC3) IN GM-CSF/CSF2RB-DEPENDENT INTESTINAL HOMEOSTASIS IN CROHN’S DISEASE
Inflammatory Bowel Disease (IBD) is comprised of two subtypes, Crohn’s disease (CD) and ulcerative colitis (UC). Genome-wide association studies (GWAS) of IBD identified 240 loci significantly associated with IBD risk. CSF2RB, one of the identified IBD… Continue reading
IBD AND THE PATIENT-PROVIDER RELATIONSHIP: DOES TRUST IMPACT TELEMEDICINE UTILIZATION?
Telemedicine use has increased during the COVID-19 pandemic, but uptake among patient populations has not been equitable. Lack of access to technology or broadband connection contributes to the digital divide, but additional factors at the provider-lev… Continue reading
NOVEL FUNCTION OF MYELOID METHYLTRANSFERASE SMYD5 IN INFLAMMATORY BOWEL DISEASE PROGRESSION
SET and MYND domain-containing protein 5 (SMYD5) is a lysine methyltransferase and broadly expressed across various tissues, including immune cells. However, the myeloid SMYD5 in inflammatory bowel disease is entirely unknown. Here, we interrogated the… Continue reading
EQUIVALENT ADVERSE OUTCOMES FOR HOME AND HOSPITAL-BASED INFUSIONS OF INFLIXIMAB IN CHILDREN AND ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE
Pediatric inflammatory bowel disease (IBD) is commonly treated with infliximab in a hospital setting or clinic where infusions are safely and effectively administered. In recent years, utilization of home infusions (HI) has increased due to reduced cos… Continue reading
NOD2 PROMOTES HOST DEFENSE AND RECOVERY INDUCING MACROPHAGE-MEDIATED INNATE LYMPHOID CELLS TYPE 3 ACTIVATION FOLLOWING FUNGAL INFECTION IN EXPERIMENTAL COLITIS
Recent studies have documented the complexity of the intestinal fungal community (‘mycobiome’) in mice, and clinical and experimental observations have shown that the mycobiome influences both gut health and disease, e.g., inflammatory bowel disease (I… Continue reading
CELL-AUTONOMOUS HEDGEHOG SIGNALING CONTROLS TH17 DIFFERENTIATION TO DRIVE INTESTINAL INFLAMMATION AND IS A DRUGGABLE TARGET FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
T helper 17 (Th17) cells play a key role in barrier protection in the gastrointestinal tract but are also key pathological drivers of Inflammatory Bowel Disease (IBD). Although a number of key transcription factors governing Th17 differentiation have b… Continue reading
MASS CYTOMETRY ANALYSIS OF CROHN’S DISEASE-LIKE PHENOTYPE OF THE ILEOANAL POUCH FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS
For patients with medically refractory ulcerative colitis (UC), total proctocolectomy and ileal pouch-anal anastomosis (IPAA) has been the definitive surgery of choice. Approximately 10% of patients who were initially diagnosed with UC and underwent an… Continue reading
GENERATION OF ANTIGEN-SPECIFIC REGULATORY T CELLS BY LACTOBACILLUS SPECIES
There is a need for novel treatments for patients with inflammatory bowel disease (IBD) who do not respond to medical therapy. It is likely that IBD arises from dysfunctional interactions between the mucosal immune system and the gut microbiome, and ma… Continue reading
INTERLEUKIN 21-INDUCED METABOLIC REPROGRAMMING DRIVES CD4 T CELL INFLAMMATORY RESPONSE DURING INTESTINAL INFLAMMATION
Significant proportion of inflammatory bowel disease (IBD) patients continue to respond inconsistently to therapies, underscoring disease complexity and the need for efficacious treatment. Interleukin 21 (IL-21), which is known to support T helper (Th)… Continue reading